Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AKBA's 10-Y Financials

Financials (Next Earnings Date: 0)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AKBA Guru Trades in Q1 2016

Paul Tudor Jones 18,498 sh (New)
Jim Simons 28,500 sh (-73.90%)
Steven Cohen 100 sh (-99.76%)
» More
Q2 2016

AKBA Guru Trades in Q2 2016

Paul Tudor Jones 18,798 sh (+1.62%)
Steven Cohen Sold Out
Jim Simons 24,300 sh (-14.74%)
» More
Q3 2016

AKBA Guru Trades in Q3 2016

Jim Simons 151,800 sh (+524.69%)
Paul Tudor Jones 18,410 sh (-2.06%)
» More
Q4 2016

AKBA Guru Trades in Q4 2016

Jim Simons 208,600 sh (+37.42%)
Paul Tudor Jones 19,728 sh (+7.16%)
» More
» Details

Insider Trades

Latest Guru Trades with AKBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:XBIT, NAS:TRVN, NAS:RXDX, NAS:MYOK, NAS:NSTG, NAS:TLGT, NAS:CARA, NAS:AVDL, NAS:CRBP, NAS:AGEN, NAS:PTI, NAS:MRUS, NAS:NVAX, NAS:MCRB, NAS:MACK, OTCPK:MEOBF, NAS:CRIS, NAS:PDLI, OTCPK:ABVC, NAS:FOMX » details
Traded in other countries:AX9.Germany,
Akebia Therapeutics Inc is a biopharmaceutical company. It is engaged in the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.

Akebia Therapeutics Inc was incorporated under the laws of the state of Delaware in February 2007. The Company is a biopharmaceutical company focused on the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease. HIF is the primary regulator of the production of red blood cells, or RBCs, in the body and a potentially novel mechanism of treating anemia. Its product candidate, AKB-6548, is being developed as a once-daily oral therapy that has successfully completed a Phase 2a proof of concept study demonstrating that AKB-6548 safely and predictably raised hemoglobin levels in patients with anemia secondary to chronic kidney disease, or CKD, not requiring dialysis.

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

EPS (TTM) $ -3.28
Short Percentage of Float5.18%
52-Week Range $7.00 - 11.07
Shares Outstanding (Mil)38.32

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 63 117 114
EPS ($) -1.93 -1.49 -2.19 -1.13
EPS w/o NRI ($) -1.93 -1.49 -2.19 -1.13
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)